FAQ (FAQ 401);FAQ (FAQ 402)
Foreo, Inc. · Decision date Oct 26, 2026
What did the FDA decide?
FDA records K261625 as a 510(k) premarket notification, with a decision dated Oct 26, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Neurology
- Decision date
- Oct 26, 2026
Regulatory record facts
- Identifier
- K261625
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Foreo, Inc.
- Product code
- NFO
- Decision code
- SESE
- Decision date
- Oct 26, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, Transcutaneous Electrical, Aesthetic Purposes.
- Applicant
- Foreo, Inc.
- Product code
- NFO
- FDA device class
- 2
FDA decision timeline
K261625 received
Application receipt date recorded by FDA.
K261625 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NFO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
FAQ (FAQ 411)K261565 | Foreo, Inc. | 510(k) clearance | Oct 22, 2026 | FDA |
| Guangdong Newdermo Biotech Co., Ltd. | 510(k) clearance | Sep 16, 2026 | FDA | |
PureLift Pro MaxK262861 | Xtreem Pulse, LLC | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Foreo, Inc.
- Headquarters
- Not reported
- Brand website
- foreo.com
- FDA applicant address
- Las Vegas, NV
Sources and methodology
- Original FDA record: K261625
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
